Showing results (41-50 of 92) with videos related to
Sort By:
Pageof 10
Cancer Research|March 15, 2008
GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosisTanya Das, Gaurisankar Sa, Cynthia Hilston, et al.The Oncologist|February 6, 2025
Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 studyMiguel Zugman, David F McDermott, Bernard J Escudier, et al.The Oncologist|December 28, 2022
Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3Luis Meza, David F McDermott, Bernard Escudier, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 6, 2009
Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunctionSoumika Biswas, Kaushik Biswas, Amy Richmond, et al.European Urology|October 16, 2012
Metabolism of kidney cancer: from the lab to clinical practiceSunil Sudarshan, Jose A Karam, James Brugarolas, et al.Cancer Causes & Control : CCC|May 8, 2021
Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approachMary E Hall, Bimal Bhindi, Amy N Luckenbaugh, et al.Journal of the National Cancer Institute|January 26, 2023
COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS)Ana F Best, Melissa Bowman, Jessica Li, et al.Cell Reports|September 22, 2021
PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiationXiaorong Gu, Francis Enane, Rita Tohme, et al.Urology Practice|June 14, 2023
Identifying Institutional Causes of Delay to Radical Cystectomy among Patients with High Risk Bladder Cancer Treated at a Tertiary Referral Center Using Process Map AnalysisNima Almassi, Katherine E Glass, Jennifer L Lonzer, et al.Clinical Genitourinary Cancer|September 12, 2022
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney CancerZeynep B Zengin, Sumanta K Pal, David F McDermott, et al.Pageof 10